Compare Morgan Stanley (MS) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Morgan Stanley vs Summit Therapeutics Inc — how do they compare? Morgan Stanley trades at $216 (market cap $338.09B), while Summit Therapeutics Inc trades at $15.5 (market cap $12.06B). The key difference: Morgan Stanley is far larger — about 28× Summit Therapeutics Inc's market cap, and Morgan Stanley pays a 2.14% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MS | SMMT | |
|---|---|---|
Market Cap | $338.09B | $12.06B |
Sector | Financials | Health |
52-Week High | $228.42 | $26.98 |
52-Week Low | $144.04 | $12.55 |
Dividend Yield | 2.14% | — |
Enterprise Value | — | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Morgan Stanley (MS) trades at $215.27, down 0.46% on the day, with a neutral technical signal. The stock shows strong fundamentals, with revenue growing from $50.2B in 2022 to $66.0B in 2025 and net income margin expanding to 27.59%. Recent earnings beats and the selection to lead the Anthropic IPO highlight operational strength. The consensus analyst price target is $239.58, implying potential upside.
The outlook is positive, supported by earnings momentum and strategic initiatives like AI integration in wealth management. Key risks include volatile cash flows from operations and high leverage, with debt-to-asset ratio rising to 26.1 in 2025. Analyst sentiment is bullish, with 55.77% recommending Buy.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
